🔗 Share this article

While the US continues making sweeping adjustments to its vaccine guidelines, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on Covid vaccinations throughout the pandemic and has zeroed in on alleged fatalities after COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Program

Health officials were set to reveal major changes to the childhood immunization program recently, synchronizing the US with Denmark’s immunization schedule, it is understood – a significant shift that would put the US at odds with many the world with no evidence for improved outcomes. The announcement has been postponed until the new year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to present at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

A Shift at the Agency

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has repeatedly called for ending specific pediatric shot schedules in the US so as to align more similar to the Danish model, a society with nationalized medicine and a population about the size of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccination policy – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has little discernible background in medication creation, regulation or leadership, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former directors of the center would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that prior appointees who led the center have had.”

CDER has an enormous portfolio at the agency, she stated.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office authorizes thousands of generic medications. There is also a biosimilars program, OTC medication office and other areas, and each of these must be looked after,” she explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership element to the role, which oversees more than 5,000 personnel. “It’s a huge leadership role, if you do it right,” Woodcock added.

Response and Controversial Programs

When asked about concerns about Dr. Høeg's credentials and whether this assignment indicates more teamwork among regulatory chiefs on vaccines, a press secretary said that the “concerns are based on inaccurate assumptions”.

“Her resume aligns with the functions of her role,” the spokesperson stated, noting the months Dr. Høeg spent guiding the agency head on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg inherits the agency head's new fast-track approval initiative, a contentious expedited therapy clearance system that reportedly worried her preceding directors. “How are these therapies being selected for this expedited pathway? Who makes the calls?” Dr. Howard asked. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards less stringent rules of most medications, aside from shots.”

Established Track Record on Vaccines

With immunizations, Høeg has a more established, if concerning, past, some experts observe. She published a study using unconfirmed crowd-sourced reports to assess the frequency of heart inflammation after COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership encompassed changing regulations for recently developed shots and discontinuing “optional” vaccines, she said post-election on a audio program. At the FDA, Høeg has reportedly floated the idea of excluding teenage boys from receiving COVID-19 vaccines.

“She is an thorough dogmatist who starts off with her preconceived notions and works backwards to retrofit the science in a extremely deceptive, fraudulent fashion,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|